Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Oncology, Cuproptosis, and Mitochondrial Disease Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FDXR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FDXR Full-Length & Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. FAD-binding domain intact. Theoretical MW confirmed. |
View FDXR Products |
| Gene Delivery | FDXR Promise-ORF / Lentivirus Full-length ORF for stable overexpression or rescue lines; mitochondrial localization studies. |
View FDXR Products |
| Benchmark Ab | Anti-FDXR Recombinant Antibody Sequence-defined rabbit monoclonal for Western, IP, and IF validation. |
View FDXR Products |
| Validator | FDXR siRNA Set For knockdown verification and specificity controls in cuproptosis/ferroptosis assays. |
View FDXR Products |
| Related Target: FDX1 | Ferredoxin 1 Direct electron acceptor; obligate redox partner for FDXR enzymatic assays; cuproptosis pathway partner. |
View FDX1 Products |
| Related Target: LIAS | Lipoic Acid Synthetase Downstream cuproptosis mediator; Fe-S cluster biogenesis; synergy screening target. |
View LIAS Products |
| Related Target: NFS1 | Cysteine Desulfurase Fe-S cluster scaffold protein; synthetic lethal partner with FDXR. |
View NFS1 Products |
| Related Target: TP53 | Tumor Protein p53 Upstream transcriptional regulator of FDXR during oxidative stress; controls apoptosis sensitivity. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic turnover & NADPH kinetics | Purified FDXR WT and active-site mutants (>95% purity); Theoretical MW verified by SDS-PAGE/Mass Spec; FAD-binding domain intact. |
| FDX1 protein-protein interaction mapping | Human FDXR + FDX1 co-expression system; validated ortholog pair for redox complex reconstitution (SPR/BLI). |
| Mitochondrial import and localization studies | Full-length FDXR with native transit peptide; suitable for import/pull-down assays. |
| Off-target flavoprotein selectivity | Homolog panel (FPR1, NQO1, CYB5R) for counter-screening; sequence-verified identities. |
| Target engagement in cellular cuproptosis | Validated FDXR siRNA + Lentivirus rescue combo for genetic proof-of-mechanism; copper ionophore synergy assays. |
| Disease modeling (mutations) | Site-directed mutant proteins (e.g., rs28365947, MMDS9B variants) available for rare mitochondriopathy evaluation. |
Live FDXR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FDXR-targeted therapeutics is accelerating at the preclinical interface of metabolic reprogramming and regulated cell death. As a critical mitochondrial NADPH-dependent oxidoreductase, FDXR has emerged as a pivotal node in ferroptosis resistance, cuproptosis susceptibility, and oxidative stress regulation. First-generation direct inhibitors remain in early discovery; however, the immediate translational value lies in pathway annotation—using FDXR as a biomarker for Fe-S cluster proficiency and as a synthetic lethal target in NFS1-deficient backgrounds. Beyond oncology, FDXR deficiency is linked to rare mitochondrial diseases (ataxia, sensorineural hearing loss) and radiation exposure biomarkers. The next R&D wave targets mitochondrial metabolic vulnerabilities through combination regimens with ferroptosis inducers, copper ionophores, and immune checkpoint inhibitors. PROTAC degraders and molecular glues targeting the FDXR-FDX1 interaction are also emerging as differentiated modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors/Modulators | Academic Consortia, Early-stage Biotech | Solid Tumors, Metabolic Disorders, ROS Sensitization | NADPH oxidase activity assay (need purified active FDXR with correct FAD binding); high-purity WT & mutant proteins. |
| Genetic Modulation (siRNA/CRISPR) | Research Institutes, Mitochondrial Disease Consortia | Oncology, Functional Genomics, FDXR-Deficiency Ataxia | Knockdown/Rescue validation (need validated siRNA and lentiviral ORF). |
| PROTAC / Degraders | Stealth Biotech Ventures | Refractory Tumors | Selectivity assay (need mutant vs WT proteins & homolog panel). |
| Combination with Ferroptosis Inducers | Pharma Pipelines | Refractory Cancers | Pathway analysis (need FDX1 and LIAS proteins for mechanism studies). |
| Gene Therapy (AAV/Lentivirus) | Rare Disease-Focused Biotechs | FDXR-associated Neuropathy, Optic Atrophy | Expression validation (need lentivirus/ORF and benchmark antibodies). |
| Biomarker Assays | Diagnostic Developers | Radiation Exposure, Oncology | Standardized controls (need benchmark antibodies and recombinant proteins). |
Key Mutations & Disease Associations
Several clinically relevant mutations in FDXR are documented:
- rs28365947 (UniProt VAR_025192): A missense variant reported in dbSNP; functional impact under investigation.
- MMDS9B-associated variants (UniProt VAR_089881, VAR_089882): Classified as uncertain significance; may contribute to mitochondrial disease phenotype (MMDS9B).
- Additional active-site mutants (e.g., affecting FAD or NADPH binding) are relevant for drug resistance and SAR studies. TarMart offers site-directed mutant proteins for these variants to support preclinical evaluation.
Related Targets & Pathway Integration
FDXR operates within a tightly connected mitochondrial redox network. The following targets are essential for comprehensive drug discovery programs:
- FDX1 (Ferredoxin 1): The sole physiological electron acceptor; required for enzymatic activity assays and PPI studies. Both full-length and mature forms available.
- LIAS (Lipoic Acid Synthetase): Downstream effector of the FDXR-FDX1 axis; critical for cuproptosis-mediated cell death. Synergy screening with copper ionophores.
- NFS1 (Cysteine Desulfurase): Provides sulfur for Fe-S cluster biogenesis; synthetic lethal partner with FDXR in certain tumor contexts.
- TP53 (p53): Upstream transcriptional regulator that controls FDXR expression under oxidative stress; relevant for understanding tumor apoptosis and radiation response.
Together, these targets form a "mitochondrial iron-sulfur metabolism" product matrix that enables complete pathway reconstitution from NADPH to lipoylation.